Immunosuppressants - Burundi

Burundi

The projected revenue for the Immunosuppressants market in Burundi is expected to reach US$0.63m in 2024.
This revenue is projected to exhibit an annual growth rate (CAGR 2024-2029) of 16.29%, leading to a market volume of US$1.34m by 2029.
When compared globally, United States is anticipated to generate the highest revenue in this market, with US$35,470.00m in 2024.
Despite the limited access to healthcare in Burundi, there is a growing demand for immunosuppressants due to the increasing prevalence of autoimmune diseases in the country.

Key regions: Australia, Germany, United Kingdom, United States, France

Market

Region

Region comparison

Currency

Analyst Opinion

The Immunosuppressants market in Burundi has shown steady growth in recent years.

Customer preferences: Burundi has a high prevalence of infectious diseases, which often require immunosuppressants for treatment. Additionally, the country has a high burden of non-communicable diseases, such as cancer and autoimmune disorders, which also require these medications.

Trends in the market: The market for immunosuppressants in Burundi is primarily driven by the public sector, which provides healthcare services to the majority of the population. The government has implemented several initiatives to increase access to these medications, such as subsidizing their cost and improving distribution networks. However, the market is also growing in the private sector as more people are able to afford private healthcare services.

Local special circumstances: Burundi has a limited healthcare infrastructure, which poses challenges for the distribution and administration of immunosuppressants. Additionally, the country has experienced political instability and conflict, which has disrupted healthcare services and supply chains.

Underlying macroeconomic factors: The Burundian economy is heavily dependent on agriculture, which has been affected by climate change and natural disasters. This has led to food insecurity and malnutrition, which can increase the risk of infectious and non-communicable diseases. The government has also struggled with budget constraints, which can limit its ability to invest in healthcare infrastructure and services.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.